SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is drawing significant attention as investors monitor its ability to sustain a breakout above key technical levels amidst a broader market trend of Bitcoin forks seeing renewed interest. The community remains deeply divided between long-term proponents betting on its transactional utility and skeptics who view the price action as speculative volatility.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust is currently at the center of intense debate regarding its long-term viability and lack of intrinsic value, with many investors actively discussing rotating out of the asset in favor of AI-focused stocks or alternative cryptocurrencies. This sentiment is heavily influenced by community speculation over market dominance, technical support levels near the $60,000 region, and concerns surrounding leveraged positioning across the broader crypto and tech sectors.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

The Health Care Select Sector SPDR Fund ($XLV) is currently a primary focus for investors as it experiences a significant structural breakout, signaling a rotation from defensive positioning into broader sector leadership. The community is actively discussing this bullish technical setup alongside rising interest in sub-sectors like biotech, noting that this accumulation is occurring even as high-beta growth names and healthcare providers show renewed relative strength.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is seeing significant momentum as investors rotate into the defense and autonomous systems sector, driven by recent news that the current administration is exploring potential funding and equity stakes in U.S. drone manufacturers. Community discussions remain highly bullish, with many participants highlighting the firm's established backlog and strategic position in hypersonic and unmanned aerial vehicle technologies as key factors differentiating it from smaller peers.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is seeing increased market volatility following reports that its largest customer, TSMC, intends to delay the adoption of high-cost high-NA EUV lithography machines until 2029 to maintain capital discipline. While some investors are tracking this as a short-term headwind, the community remains divided between those capitalizing on the dip as a long-term opportunity and others concerned about the potential impact on future equipment demand.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token (VVV) is experiencing heightened community interest driven by its expanding AI utility and strategic tokenomics, including ongoing discretionary burn programs and supply reduction initiatives. Investors are closely monitoring the project's ability to maintain upward momentum as it navigates the competitive AI-crypto sector, with many participants actively discussing potential price discovery and long-term utility.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

The Direxion Daily South Korea Bull 3X Shares (KORU) is experiencing extreme volatility as community discussions focus on intense technical selling driven by Korean pension fund rebalancing and a crackdown on high-leverage trading. Despite the aggressive sell-off, investors remain sharply divided, with many debating whether the current price action represents a catastrophic structural break or a massive discount buying opportunity ahead of upcoming memory-sector catalysts like the SK Hynix IPO and KORU's scheduled 20-for-1 forward split.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM shares are trending as investors weigh a binding $35 acquisition agreement against a rival $37.50 offer from an Israeli group, all while monitoring the potential for additional dividends before the deal concludes. The community remains focused on the impact of surging container freight rates and the strategic implications of keeping the company under Israeli control.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is experiencing significant momentum and investor interest, driven by a strong fundamental turnaround, robust membership growth, and high-conviction insider buying from leadership. Community sentiment highlights a shift toward viewing the stock as a breakout leader in the healthcare sector, with active discussions focusing on its long-term potential as a digital health disruptor.

Netskope, Inc. engages in the provision of cloud based security solutions. It offers business developing analytics for visibility, policy enforcement and other cloud solutions. Its products include Netskope one SASE, Netskope one SSE, cloud access security broker, next generation secure web gateway, private access, cloud firewall, SD-WAN and skopeAI. The company was founded by Sanjay Beri, Lebin Cheng, Ravishankar Ithal, and Krishna Narayanaswamy in October 2012 and is headquartered in Santa Clara, CA.

Netskope Inc. - Ordinary Shares - Class A

Netskope (NTSK) is attracting significant investor attention as market participants debate the stock's long-term potential following recent volatility and ongoing cybersecurity demand. The community is actively discussing the stock's role in the AI-driven threat landscape, with many weighing the bull casebased on strong RPO growth and enterprise stickinessagainst concerns regarding insider lock-up periods and overall SaaS sector performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data

Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.

Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?

Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.

PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire WARREN, N.J., June 17, 2026 WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced...

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes PR Newswire WARREN, N.J., June 15, 2026 Refinancing transaction with proceeds to be utilized to...

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes PR Newswire WARREN, N.J., June 15, 2026 Proceeds to be used to repurchase or repay 2026 convertible...

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

PTC Therapeutics Inc

PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PTCTPTC Therapeutics Inc

Fundamentals

Latest PTCT News